Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

Sung-Hyun Kim,1 Hari Menon,2 Saengsuree Jootar,3 Tapan Saikia,4 Jae-Yong Kwak,5 Sang-Kyun Sohn,6 Joon Seong Park,7 Seong Hyun Jeong,7 Hyeoung Joon Kim,8 Yeo-Kyeoung Kim,8 Suk Joong Oh,9 Hawk Kim,10 Dae Young Zang,11 Joo Seop Chung,12 Ho Jin Shin,12 Young Rok Do,13 Jeong-A Kim,14 Dae-Young Kim,15 Chul Won Choi,15 Sahee Park,17 Hye Lin Park,18 Gong Yeal Lee,18 Dae Jin Cho,18 Jae Soo Shin,18 and Dong-Wook Kim17,19

1Dong-A University Medical Center, Busan, South Korea; 2Tata Memorial Hospital, Parel, Mumbai, India; 3Faculty of Medicine, Rangsimha Hospital, Chiang Mai, Thailand; 4Prince Aly Khan Hospital, Maraghaon, Mumbai, India; 5Chonbuk National University Medical School & Hospital, Jeonju, South Korea; 6Kyungpook National University Hospital, Daegu, South Korea; 7Ajou University Hospital, Suwon, South Korea; 8Chonnam National University Hospital, Gwangju, South Korea; 9Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; 10Ulсан University Hospital, Il-Young Pharm. Co. Ltd., Yongin, South Korea; and 11Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea

©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.096776
Manuscript received on August 15, 2013. Manuscript accepted on March 31, 2014.
Correspondence: dwkim@catholic.ac.kr

Online Supplementary Figure S1

By 12 months 90.3%
69.6%  P = 0.0397

Probability of PFS

No of events Censored
N mutation No mutation
63 58
14 10

Months since treatment